• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对接和定量构效关系研究 3-氟-4-(吡咯并[2,1-f][1,2,4]三嗪-4-基氧基)苯胺、3-氟-4-(1H-吡咯并[2,3-b]吡啶-4-基氧基)苯胺和 4-(4-氨基-2-氟苯氧基)-2-吡啶基胺衍生物作为 c-Met 激酶抑制剂。

Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors.

机构信息

Centro de Bioinformática y Simulación Molecular, Facultad de Ingeniería en Bioinformática, Universidad de Talca, 2 Norte 685, Casilla 721, Talca, Chile.

出版信息

J Comput Aided Mol Des. 2011 Apr;25(4):349-69. doi: 10.1007/s10822-011-9425-1. Epub 2011 Apr 13.

DOI:10.1007/s10822-011-9425-1
PMID:21487786
Abstract

We have performed docking of 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline (FPTA), 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline (FPPA), and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine (AFPP) derivatives complexed with c-Met kinase to study the orientations and preferred active conformations of these inhibitors. The study was conducted on a selected set of 103 compounds with variations both in structure and activity. Docking helped to analyze the molecular features which contribute to a high inhibitory activity for the studied compounds. In addition, the predicted biological activities of the c-Met kinase inhibitors, measured as IC(50) values were obtained by using quantitative structure-activity relationship (QSAR) methods: Comparative molecular similarity analysis (CoMSIA) and multiple linear regression (MLR) with topological vectors. The best CoMSIA model included steric, electrostatic, hydrophobic, and hydrogen bond-donor fields; furthermore, we found a predictive model containing 2D-autocorrelation descriptors, GETAWAY descriptors (GETAWAY: Geometry, Topology and Atom-Weight AssemblY), fragment-based polar surface area (PSA), and MlogP. The statistical parameters: cross-validate correlation coefficient and the fitted correlation coefficient, validated the quality of the obtained predictive models for 76 compounds. Additionally, these models predicted adequately 25 compounds that were not included in the training set.

摘要

我们对 3-氟-4-(吡咯并[2,1-f][1,2,4]三嗪-4-基氧基)苯胺(FPTA)、3-氟-4-(1H-吡咯并[2,3-b]吡啶-4-基氧基)苯胺(FPPA)和 4-(4-氨基-2-氟苯氧基)-2-吡啶基胺(AFPP)与 c-Met 激酶的复合物进行了对接,以研究这些抑制剂的取向和优选的活性构象。该研究针对一组结构和活性均有变化的 103 种化合物进行了研究。对接有助于分析对研究化合物具有高抑制活性的分子特征。此外,通过定量构效关系(QSAR)方法:比较分子相似性分析(CoMSIA)和拓扑向量的多元线性回归(MLR),获得了 c-Met 激酶抑制剂的预测生物学活性,以 IC(50)值表示。最佳的 CoMSIA 模型包括立体、静电、疏水和氢键供体场;此外,我们发现了一个包含二维自相关描述符、GETAWAY 描述符(GETAWAY:几何、拓扑和原子权重组装)、基于片段的极性表面积(PSA)和 MlogP 的预测模型。交叉验证相关系数和拟合相关系数等统计参数验证了获得的预测模型对 76 种化合物的质量。此外,这些模型还适当地预测了 25 种未包含在训练集中的化合物。

相似文献

1
Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors.对接和定量构效关系研究 3-氟-4-(吡咯并[2,1-f][1,2,4]三嗪-4-基氧基)苯胺、3-氟-4-(1H-吡咯并[2,3-b]吡啶-4-基氧基)苯胺和 4-(4-氨基-2-氟苯氧基)-2-吡啶基胺衍生物作为 c-Met 激酶抑制剂。
J Comput Aided Mol Des. 2011 Apr;25(4):349-69. doi: 10.1007/s10822-011-9425-1. Epub 2011 Apr 13.
2
Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.采用分子模拟方法研究新型 2-氨基吡啶衍生物作为有效和选择性 c-Met 激酶型 1 抑制剂的结合模式。
Molecules. 2020 Dec 24;26(1):52. doi: 10.3390/molecules26010052.
3
Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints.使用分子指纹预测一系列1H-吡咯并[2,3-b]吡啶衍生物作为c-Met可能抑制剂的细胞毒性活性。
J Recept Signal Transduct Res. 2019 Aug;39(4):295-303. doi: 10.1080/10799893.2019.1676258. Epub 2019 Oct 28.
4
Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.含1H-吡咯并[2,3-b]吡啶部分的苯基嘧啶-羧酰胺衍生物作为c-Met抑制剂的合成及对接研究
Bioorg Med Chem. 2016 Apr 15;24(8):1749-56. doi: 10.1016/j.bmc.2016.02.046. Epub 2016 Mar 3.
5
Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors.分子对接和 3D-QSAR 研究 4-(1H-吲唑-4-基)苯氨基和氨基吡唑并吡啶脲衍生物作为激酶插入结构域受体 (KDR) 抑制剂。
J Mol Model. 2012 Mar;18(3):1207-18. doi: 10.1007/s00894-011-1146-9. Epub 2011 Jun 22.
6
Pyrrolo[3,2-d]pyrimidine derivatives as type II kinase insert domain receptor (KDR) inhibitors: CoMFA and CoMSIA studies.作为II型激酶插入结构域受体(KDR)抑制剂的吡咯并[3,2-d]嘧啶衍生物:比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)研究
Int J Mol Sci. 2012;13(2):2387-2404. doi: 10.3390/ijms13022387. Epub 2012 Feb 22.
7
3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.基于 3D-QSAR、分子动力学模拟和分子对接的吡啶并氨基托烷和四氢喹唑啉类 mTOR 抑制剂研究。
Mol Divers. 2017 Aug;21(3):741-759. doi: 10.1007/s11030-017-9752-9. Epub 2017 Jun 2.
8
Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.发现带有1,2,3-三唑部分的新型吡咯并[2,3-b]吡啶衍生物作为c-Met激酶抑制剂
Bioorg Med Chem Lett. 2016 Apr 1;26(7):1680-4. doi: 10.1016/j.bmcl.2016.02.059. Epub 2016 Feb 21.
9
Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.发现带有哒嗪酮部分的新型吡咯并吡啶/嘧啶衍生物作为c-Met激酶抑制剂
Eur J Med Chem. 2017 Dec 1;141:538-551. doi: 10.1016/j.ejmech.2017.10.027. Epub 2017 Oct 13.
10
Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.含芳腙部分的 1H-吡咯并[2,3-b]吡啶衍生物的合成、生物评价及 doking 研究作为 c-Met 抑制剂。
Eur J Med Chem. 2018 Feb 10;145:315-327. doi: 10.1016/j.ejmech.2017.12.078. Epub 2017 Dec 27.

引用本文的文献

1
Docking, Interaction Fingerprint, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) of Sigma1 Receptor Ligands, Analogs of the Neuroprotective Agent RC-33.西格玛1受体配体(神经保护剂RC-33的类似物)的对接、相互作用指纹图谱及三维定量构效关系(3D-QSAR)
Front Chem. 2019 Jul 11;7:496. doi: 10.3389/fchem.2019.00496. eCollection 2019.
2
2D-SAR, Topomer CoMFA and molecular docking studies on avian influenza neuraminidase inhibitors.关于禽流感神经氨酸酶抑制剂的二维结构活性关系(2D-SAR)、拓扑分子场分析(Topomer CoMFA)及分子对接研究
Comput Struct Biotechnol J. 2018 Dec 7;17:39-48. doi: 10.1016/j.csbj.2018.11.007. eCollection 2019.
3

本文引用的文献

1
Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site.计算研究 N1 取代的吡唑衍生物与 B-raf 激酶的相互作用:活性位点入口处的不寻常水线氢键网络和新相互作用。
J Chem Inf Model. 2010 Jun 28;50(6):1101-12. doi: 10.1021/ci100049h.
2
Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.新型联苯甲胺基 Met 激酶抑制剂的设计、合成及构效关系研究。
Bioorg Med Chem Lett. 2010 May 1;20(9):2998-3002. doi: 10.1016/j.bmcl.2010.01.042. Epub 2010 Jan 20.
3
Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?
不考虑现有结构数据,仅将分子对接得分最高的构象作为最佳解决方案是否可靠?
Molecules. 2018 Apr 28;23(5):1038. doi: 10.3390/molecules23051038.
4
(1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.(1S,2E,4S,7E,11E)-2,7,11-西柏三烯-4,6-二醇半合成类似物作为新型c-Met抑制剂用于控制c-Met依赖性乳腺恶性肿瘤。
Bioorg Med Chem. 2016 Nov 15;24(22):5748-5761. doi: 10.1016/j.bmc.2016.09.032. Epub 2016 Sep 13.
5
Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA.使用对接、定量构效关系、分子动力学和MM-GBSA研究凝血酶抑制剂的差异活性
PLoS One. 2015 Nov 24;10(11):e0142774. doi: 10.1371/journal.pone.0142774. eCollection 2015.
6
Insights into the interactions between maleimide derivates and GSK3β combining molecular docking and QSAR.结合分子对接和定量构效关系深入了解马来酰亚胺衍生物与糖原合成酶激酶3β之间的相互作用。
PLoS One. 2014 Jul 10;9(7):e102212. doi: 10.1371/journal.pone.0102212. eCollection 2014.
7
Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery.基于结构的合理药物设计的当前进展标志着药物发现领域的一种新思维方式。
Comput Struct Biotechnol J. 2013 Apr 2;5:e201302011. doi: 10.5936/csbj.201302011. eCollection 2013.
8
Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3β.作为 GSK3β 抑制剂的恶二唑衍生物的对接和定量构效关系。
Mol Divers. 2014 Feb;18(1):149-59. doi: 10.1007/s11030-013-9483-5. Epub 2013 Oct 1.
9
Drug design for ever, from hype to hope.药物设计永不止步,从炒作到希望。
J Comput Aided Mol Des. 2012 Jan;26(1):137-50. doi: 10.1007/s10822-011-9519-9. Epub 2012 Jan 18.
10
Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.对接、分子动力学和定量构效关系研究作为 HIV-1 逆转录酶抑制剂的 HEPTs 和 DABOs。
J Mol Model. 2012 May;18(5):2185-98. doi: 10.1007/s00894-011-1236-8. Epub 2011 Sep 27.
Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.
兰索拉唑和阿替洛尔与 tau 聚合物的选择性相互作用:在阿尔茨海默病诊断中的潜在新临床用途。
J Alzheimers Dis. 2010;19(2):573-89. doi: 10.3233/JAD-2010-1262.
4
Small molecule c-Met kinase inhibitors: a review of recent patents.小分子 c-Met 激酶抑制剂:近期专利述评。
Expert Opin Ther Pat. 2010 Feb;20(2):159-77. doi: 10.1517/13543770903514137.
5
Computational study of the interactions between guanine derivatives and cyclin-dependent kinase 2 (CDK2) by CoMFA and QM/MM.通过 CoMFA 和 QM/MM 对鸟嘌呤衍生物与细胞周期蛋白依赖性激酶 2(CDK2)相互作用的计算研究。
J Chem Inf Model. 2010 Jan;50(1):110-22. doi: 10.1021/ci900302z.
6
Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.分析 c-Met 激酶结构域复合物:一种新的特定催化位点受体模型,用于定义 ATP 竞争配体的结合模式。
Chem Biol Drug Des. 2009 Dec;74(6):560-70. doi: 10.1111/j.1747-0285.2009.00895.x.
7
Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies.茶儿茶素抑制人结肠癌细胞中肝细胞生长因子受体(MET激酶)活性:动力学和分子对接研究。
J Med Chem. 2009 Nov 12;52(21):6543-5. doi: 10.1021/jm901330e.
8
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.发现并优化强效和选择性的三唑并吡啶嗪系列 c-Met 抑制剂。
Bioorg Med Chem Lett. 2009 Nov 15;19(22):6307-12. doi: 10.1016/j.bmcl.2009.09.096. Epub 2009 Sep 27.
9
Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.激酶抑制剂数据建模与基于片段方法的全新抑制剂设计
J Med Chem. 2009 Oct 22;52(20):6456-66. doi: 10.1021/jm901147e.
10
Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.发现4-氮杂吲哚作为c-Met激酶的新型抑制剂。
Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4. doi: 10.1016/j.bmcl.2009.03.110. Epub 2009 Mar 27.